Boryung to boost sales of Kanarb in Central and South America

Published: 2011-12-06 06:58:00

Updated: 2011-12-06 06:58:00

Boryung Pharmaceutical Co., one of Korea's largest pharmaceutical companies, said recently that it will strengthen a strategic alliance with Stendhal SA, a leading pharmaceutical firm in Mexico in an effort to expand the sales of Kanarb (fimasartan) in 13 Central and South American countries.

...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK